Hereditary Thrombophilia Risk Factors In Patients With Venous Thromboembolism

Venous thromboembolic disease (VTD) is a serious cause of mortality and morbidity with an incidence of 0.1% per year. The etiology of VTD is multifactorial and associated with acquired and hereditary conditions. The aim of our study was to investigate the presence of rare genetic mutations in VTD patients and to evaluate their distribution according to thrombosis sites. The study group consisted of 107 patients who underwent genetic testing for thrombophilia due to VTD between 2015 and 2017. Patients with VTD who underwent thrombophilic genetic examination by polymerase chain reaction method were included in the study. Antithrombin III, protein C and protein S deficiency patients diagnosed with biochemical tests were excluded from the study. The demographic characteristics and clinical results of the patients were obtained from the hospital archive. The control group consisted of 112 healthy individuals randomly selected from the community. The patient group and the control group were compared. The mean age of the patients was 39.6 years. The female/male ratio was 1.7. Advanced age and female gender were statistically significantly more frequent in the patient group (In both, p=0.0001). Factor V G1691A and B-Fibrinogen-455 genetic defects were statistically significantly higher in the patient group (Respectively; p=0.008, p=0.049). The most frequent (54.2%) PAI-4G&5G heterozygous gene defect was found in the patients. Deep venous thrombosis was detected in 54.2%, intraabdominal VTD in 4.7%, pulmonary embolism in 27.1%, and cerebral venous thrombosis in 30.8% of the VTD patients. Thrombophilic genetic mutations are not uncommon in patients with VTD. Thrombophilic genetic mutations in VTD etiology and in selected patients should be investigated. In patients without known thrombophilia mutations, rare thrombophilic mutations should be examined.

PDF

___

1. Ho WK, Hankey GJ, Lee CH, Eikelboom JW. Venous thromboembolism: diagnosis and management of deep venous thrombosis. Med J Aust 2005; 182: 476-481.

2. Segal JB, Eng J, Tamariz LJ, Bass EB. Review of the Evidence on Diagnosis of Deep Venous Thrombosis and Pulmonary Embolism. Ann Fam Med 2007; 5: 63-73.

3. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis 2016; 41: 3-14.

4. Bezgin T, Kaymaz C, Akbal Ö, Yılmaz F, Tokgöz HC, Özdemir N. Thrombophilic Gene Mutations in Relation to Different Manifestations of Venous Thromboembolism: A Single Tertiary Center Study. Clin Appl Thromb Hemost 2018; 24: 100- 106.

5. Walker ID, Greaves M, Preston FE. Haemostasis and Thrombosis Task Force; British Committee for Standards in Haematology: Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114: 512-528.

6. Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol 2015; 12: 464-474.

7. Klaassen IL, van Ommen CH, Middeldorp S. Manifestations and clinical impact of pediatric inherited thrombophilia. Blood 2015; 125: 1073- 1077.

8. Esmon CT. Basic Mechanisms and Pathogenesis of Venous Thrombosis. Blood Rev 2009; 23: 225- 229.

9. Stone J, Hangge P, Albadawi H, et al. Deep vein thrombosis: pathogenesis, diagnosis, and medical management. Cardiovasc Diagn Ther 2017; 7: 276-284.

10. Khan S, Dickerman JD. Hereditary thrombophilia. Thromb J 2006; 4: 15.

11. Bargahi N, Ghorbian S, Zonouzi AA, Zonouzi AP. Genetic susceptibility to deep venous thromboembolism: the roles of inherited thrombophilia polymorphisms. Blood Coagul Fibrinolysis 2016; 27: 308-312.

12. Colucci G, Tsakiris DA. Thrombophilia Screening: Universal, Selected, or Neither? Clin Appl Thromb Hemost 2017; 23: 893-899.

13. Yilmaz S, Gunaydin S. Inherited risk factors in low-risk venous thromboembolism in patients under 45 years. Interact Cardiovasc Thorac Surg 2015; 20: 21-23.

14. Barsoum MK, Heit JA, Ashrani AA, Leibson CL, Petterson TM, Bailey KR. Is progestin an independent risk factor for incident venous thromboembolism? A population-based casecontrol study. Thromb Res 2010; 126: 373-378.

15. White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003; 90: 446-455.

16. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166: 458-464.

17. James AH. Venous thromboembolism in pregnancy. Arterioscler Thromb Vasc Biol 2009; 29: 326-331.

18. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000; 160: 761-768.

19. Huang W, Goldberg RJ, Anderson FA, Kiefe CI, Spencer FA. Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009). Am J Med 2014; 127: 829-839.

20. Kreidy R. Influence of acquired and genetic risk factors on the prevention, management, and treatment of thromboembolic disease. Int J Vasc Med 2014; 2014: 859726.

21. Akar N, Akar E, Misirlioğlu M, Avcu F, Yalçin A, Cin Ş. Search for genetic factors favoring thrombosis in Turkish population. Thrombosis research 1998; 92: 79-82.

22. Shemirani AH, Haramura G, Bagoly Z, Muszbek L. The combined effect of fibrin formation and factor XIII A subunit Val34Leu polymorphism on the activation of factor XIII in whole plasma. Biochimica et Biophysica Acta 2006; 1764: 1420- 1423.

23. Renner W, Cichocki L, Forjanics A, Köppel H, Gasser R, Pilger E. G-455A polymorphism of the fibrinogen beta gene and deep vein thrombosis. Eur J Clin Invest 2002; 32: 755-758.

24. Tan J-Y, Lian L-H, Nadarajan VS. Genetic polymorphisms of human platelet antigens-1 to - 6, and -15 in the Malaysian population. Blood Transfus 2012; 10: 368-376.

25. Aboud O, Mrak RE, Boop F, Griffin ST. Apolipoprotein epsilon 3 alleles are associated with indicators of neuronal resilience. BMC Med 2012; 10: 35.